Autologous Tumor Infiltrating Lymphocyte (TIL) Platform

Champions Oncology's ex vivo 3D co-culture platform for Immuno-Oncology therapeutic testing 


Champions Oncology has launched an innovative new platform enabling Immuno-Oncology researchers the ability to test their therapeutics in a 3D organoid assay that can mimic mechanism of action. The Autologous TIL platform is an ex vivo 3D co-culture platform developed and optimized to interrogate the responses of your Immuno-Oncology drugs with a tumor-specific microenvironment in only 4 days using PDX-O (patient-derived xenograft organoids) collected with matched, autologous TIL samples. 




The scientific endpoints of this platform are: imaging using confocal microscopy, HCA assay with tumor cytotoxicity and TIL infiltration readouts, flow cytometry assessment of TIL cellular constituents and supernant cytokine assessment by Luminex.



Learn more about the autologous TIL Ex vivo platform